Heron Therapeutics reported its fourth-quarter and full-year 2023 financial results, achieving a quarterly record of $5.6 million in net product sales from Zynrelef. The company also reported $107.9 million in revenue from its oncology care franchise. CEO Craig Collard expressed optimism for the company’s long-term success and profitability, attributing positive momentum to strategic decisions made over the past year. Heron Therapeutics reaffirmed its full-year 2024 financial guidance for product revenues, net, adjusted operating expenses, and adjusted earnings before interest, taxes, depreciation, and amortization. The company aims to provide substantial value and solutions in acute care and oncology care settings.
Source link
Heron Therapeutics reports fourth-quarter, full-year 2023 financial results
